The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.

Kiniksa Pharmaceuticals International announced that it has begun enrolling participants for the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.

AEON Biopharma revealed their intention to proceed with a crucial clinical development trial in cervical dystonia for their main product, ABP-450 (prabotulinumtoxinA) injection.

Eli Lilly and Company along with Morphic Holding, Inc. have revealed a formal agreement in which Lilly will purchase Morphic.

Ligand Pharmaceuticals Incorporated revealed that it has finalized a definitive contract to purchase APEIRON Biologics AG.

iTeos Reports Initial Patient Dosed in GALAXIES Lung-301 Phase 3 Trial, Securing $35 Million Milestone Payment from GSK.

SciRhom GmbH has declared the successful conclusion of a EUR 63 million Series A funding round.

Immorna Biotherapeutics Gets U.S. FDA IND Approval for JCXH-211 IV Phase 1/2 Trial Alone and with Checkpoint Inhibitor in Advanced Solid Tumor Patients.

Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.

Cartesian Therapeutics, revealed that the initial patient has been treated in its Phase 2 open-label clinical study assessing Descartes-08 in individuals with systemic lupus erythematosus.

Checkpoint Therapeutics has announced the successful resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for cosibelimab.